Shares of Integra LifeSciences Holdings Corporation IART, a global leader in medical technology, scaled a new 52-week high of $45.50 on Jan 10, closing a tad lower at $44.90.
An expected earnings growth rate of 11.3% indicates the stock’s potential for further appreciation in the near future.
Favorable Stock Performance
A glimpse at Integra’s share price movement reveals a stupendous one-year return of approximately 39.4%, way better than the Zacks classified Medical-Biomed/ Genetics sub-industry’s decline of roughly 13.5% over the same timeframe.
While the company’s current earnings yield is 4.2%, far better than the industry average of -17.2%, its projected sales growth for the current year stands at 7.6%.
Integra registered positive earnings surprises in the last four quarters, the average being 3.6%.
Meanwhile, the stock carries a Zacks Rank #3 (Hold) and has a remarkable market cap of $3.34 billion.
The current estimate revision trend for the stock is pretty favorable for the full year with one estimate going north in the past seven days, compared to no movement in the opposite direction. Notably, the full-year estimates are pegged at $1.75 per share at the moment.
Integra LifeSciences Holdings Corporation Price and Consensus
Integra LifeSciences Holdings Corporation Price and Consensus | Integra LifeSciences Holdings Corporation Quote
Of the recent developments, Integra has signed a definitive agreement to take over Derma Sciences Inc. DSCI for $7.00 per share. Per management, Derma Sciences has strengthened Integra’s regenerative technology capabilities by adding its amniotic tissue-based product line to Integra’s portfolio.
Notably, the transaction is expected to close by the first quarter of 2017. Meanwhile, Derma Sciences has a Zacks Rank #3 (Hold) and has a projected sales growth of 19.7% for the current year.
Meanwhile, Integra recently provided an update on the fourth quarter and full-year guidance.
The company forecasts fourth quarter and full-year 2016 revenues of $256 million and $992 million, respectively. Notably, these figures are at the lower end of the previously provided guidance.
Coming to organic growth prospects of the stock, excluding the impact of foreign currency changes, Integra expects 7% growth for the fourth quarter. However, for the full year, organic revenues are expected to multiply at a rate of 9%.
Meanwhile, Integra expects full-year 2017 organic revenue in the range of $1.05 billion to $1.07 billion, multiplying at the rate of 7% to 8.5%. The company projects full-year 2017 adjusted earnings in the band of $1.91 to $1.97 per share, growing at low double digits on a year-over-year basis.
Stocks to Consider
Better-ranked stocks in the broader medical sector include Glaukos Corporation GKOS and Penumbra Inc. PEN. Notably, Glaukos Corporation and Penumbra sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Glaukos Corporation has a long-term expected earnings growth rate of approximately 25%. Notably, the stock represents an impressive one-year return of 52.1%.
Penumbra has a long-term expected earnings growth rate of 20%. Notably, the stock represents an impressive one-year return of almost 29.7%.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest buy-and-hold tickers for the entirety of 2017?
Who wouldn't? As of early December, the 2016 Top 10 produced 5 double-digit winners including oil and natural gas giant Pioneer Natural Resources which racked up a stellar +50% gain. The new list is painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. Be among the very first to see it>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Integra LifeSciences Holdings Corporation (IART): Free Stock Analysis Report
Derma Sciences, Inc. (DSCI): Free Stock Analysis Report
Penumbra, Inc. (PEN): Free Stock Analysis Report
Glaukos Corporation (GKOS): Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research